Compare Johnson & Johnson (JNJ) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Ryanair Holdings plc — how do they compare? Johnson & Johnson trades at $260.1 (market cap $618.09B), while Ryanair Holdings plc trades at $53.06 (market cap $27.11B). The key difference: Johnson & Johnson is far larger — about 22.8× Ryanair Holdings plc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Ryanair Holdings plc for 72 Days on average.
| JNJ | RYAAY | |
|---|---|---|
Market Cap | $618.09B | $27.11B |
Volume | 6,050,983 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $278.43 | $73.82 |
52-Week Low | $186.00 | $51.95 |
Typical Hold Time | 129 Days | 72 Days |
Enterprise Value | $646.37B | $24.18B |
Dividend Yield | 2.09% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
RYAAY trades at $53.1, down 5.18% on the day, reflecting a bearish technical signal amid mixed earnings performance. The company maintains strong profitability with a 12.13% net income margin and 22.41% ROE, while valuation metrics like a P/E of 13.43 appear attractive. Recent news highlights CEO commentary on Boeing MAX 10 certification delays and concerns over rising fuel costs impacting future airfares.
The stock presents a value opportunity given its low valuation multiples and robust cash flow generation, but faces near-term headwinds from volatile fuel prices and a lowered FY27 traffic outlook. Analyst consensus remains moderately bullish, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
